
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
Jim Miller, President of PharmSource, speaks with BioPharm International.
Jim Miller, President of PharmSource, spoke with BioPharm International about the contract services market, and CMO acquisition activity.






